MC 📈 Moelis - Overview

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US60786M1053

MC: Mergers, Acquisitions, Restructurings, Capital Markets, Advisory Services

Moelis & Company is a global investment banking advisory firm that provides a range of services to its clients, including mergers and acquisitions, recapitalizations, and restructurings, as well as advice on capital markets transactions and other corporate finance matters. The firm's expertise also extends to strategic, capital structure, and private funds advisory, allowing it to offer comprehensive solutions to its clients. By operating in a variety of sectors, including North and South America, Europe, the Middle East, Asia, and Australia, Moelis & Company is well-positioned to advise clients on cross-border transactions and other complex deals.

The company's client base is diverse, comprising public multinational corporations, middle market private companies, financial sponsors, entrepreneurs, governments, and sovereign wealth funds. This broad range of clients allows Moelis & Company to leverage its expertise and network to provide tailored advice and solutions to each client, regardless of their size or sector. With a strong presence in key financial hubs around the world, the firm is able to offer its clients access to a global network of investors, lenders, and other market participants, facilitating the execution of complex transactions and deals.

Founded in 2007 by Ken Moelis, the company has established itself as a leading independent investment banking advisory firm, with a reputation for providing high-quality advice and service to its clients. Headquartered in New York, New York, Moelis & Company is listed on the New York Stock Exchange (NYSE) under the ticker symbol MC, and its common stock is classified under the GICS Sub Industry of Investment Banking & Brokerage. With a global footprint and a commitment to delivering exceptional results for its clients, Moelis & Company is well-positioned for continued growth and success in the investment banking advisory sector.

Additional Sources for MC Stock

MC Stock Overview

Market Cap in USD 5,337m
Sector Financial Services
Industry Capital Markets
GiC Sub-Industry Investment Banking & Brokerage
IPO / Inception 2014-04-16

MC Stock Ratings

Growth 5y 76.2%
Fundamental 30.8%
Dividend 43.8%
Rel. Strength Industry 14.4
Analysts 2.33/5
Fair Price Momentum 83.37 USD
Fair Price DCF 70.63 USD

MC Dividends

Dividend Yield 12m 3.25%
Yield on Cost 5y 10.54%
Annual Growth 5y -5.88%
Payout Consistency 84.7%

MC Growth Ratios

Growth Correlation 3m 64.2%
Growth Correlation 12m 85.2%
Growth Correlation 5y 68.1%
CAGR 5y 26.45%
CAGR/Mean DD 5y 1.29
Sharpe Ratio 12m 0.90
Alpha 7.19
Beta 1.12
Volatility 37.99%
Current Volume 1260k
Average Volume 20d 589.3k
What is the price of MC stocks?
As of December 22, 2024, the stock is trading at USD 73.81 with a total of 1,260,007 shares traded.
Over the past week, the price has changed by -0.16%, over one month by +0.59%, over three months by +6.14% and over the past year by +37.72%.
Is Moelis a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Moelis is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 30.81 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of MC as of December 2024 is 83.37. This means that MC is currently undervalued and has a potential upside of +12.95% (Margin of Safety).
Is MC a buy, sell or hold?
Moelis has received a consensus analysts rating of 2.33. Therefor, it is recommend to sell MC.
  • Strong Buy: 0
  • Buy: 0
  • Hold: 6
  • Sell: 0
  • Strong Sell: 3
What are the forecast for MC stock price target?
According to ValueRays Forecast Model, MC Moelis will be worth about 92.8 in December 2025. The stock is currently trading at 73.81. This means that the stock has a potential upside of +25.73%.
Issuer Forecast Upside
Wallstreet Target Price 70.7 -4.2%
Analysts Target Price 39.2 -46.9%
ValueRay Target Price 92.8 25.7%